The Journal of Pain
Volume 11, Issue 4 , Pages 360-368 , April 2010

Impact of Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy on Health Care Costs

  • Robert H. Dworkin

      Affiliations

    • Departments of Anesthesiology and Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York
    • Corresponding Author InformationAddress reprint requests to Dr Robert H. Dworkin, Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 604, Rochester, NY 14642.
    • ,
  • Daniel C. Malone

      Affiliations

    • University of Arizona, Tucson, Arizona and Strategic Therapeutics, LLC, Tucson, Arizona
    • ,
  • Christopher J. Panarites

      Affiliations

    • NeurogesX, Inc, San Mateo, California
    • ,
  • Edward P. Armstrong

      Affiliations

    • University of Arizona, Tucson, Arizona and Strategic Therapeutics, LLC, Tucson, Arizona
    • ,
  • Sissi V. Pham

      Affiliations

    • Sissi Pham Consulting, Inc, Chapel Hill, North Carolina

Received 3 April 2009 ,Revised 17 July 2009 ,Accepted 8 August 2009.

References 

  1. Attal N, Cruccu G, Haanpää M, Hansson P, Jensen TS, Nurmikko T, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13:1153–1169
  2. Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: A review. Pain Med. 2007;8(suppl 2):S50–S62
  3. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain. 2004;5:143–149
  4. Bouhassira D, Lantéri-Minet M, Attal , Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics ion the general population. Pain. 2008;136:380–387
  5. Boulton AJM, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004;27:1458–1486
  6. Boulton AJM, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care. 2005;28:956–962
  7. Brisson M, Edmunds WJ, Gay NJ. Varicella vaccination: Impact of vaccine efficacy on the epidemiology of VZV. J Med Virol. 2003;70(suppl 1):S31–S37
  8. Cepeda MS, Farrar JT. Economic evaluation of oral treatments for neuropathic pain. J Pain. 2006;7:119–128
  9. Charlson ME, Pompei P, Ales KL, McKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373–383
  10. Cruccu G, Aziz TZ, Garcia-Larrea L, Hansson P, Jensen TS, Lefaucheur JP, et al. EFNS guidelines on neurostimulation therapy for neuropathic pain. Eur J Neurol. 2007;14:952–970
  11. Dworkin RH, Gnann JW, Oaklander AL, Raja S, Schmader KE, Whitley RJ. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain. 2008;9(suppl 1):S37–S44
  12. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44(Suppl 1):S1–S26
  13. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Jensen TS, Kalso EA, et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain. 2007;132:237–251
  14. Dworkin RH, Panarites C, Chen C. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on healthcare costs. J Pain. 2009;10(suppl 1):S17
  15. Dworkin RH, White R, O'Connor AB, Baser O, Hawkins K. Health care costs of acute and chronic pain associated with a diagnosis of herpes zoster. J Am Geriatr Soc. 2007;55:1168–1175
  16. Dworkin RH, White R, O'Connor AB, Hawkins K. Healthcare expenditure burden of persisting herpes zoster pain. Pain Med. 2008;9:348–353
  17. Garnett GP, Ferguson NM. Predicting the effect of varicella vaccine on subsequent cases of zoster and varicella. Rev Med Virol. 1996;6:151–161
  18. Gauthier A, Breuer J, Carrington D, Martin M, Rémy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect. 2009;137:38–47
  19. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003;26:1790–1795
  20. Gore M, Brandenburg NA, Hoffman DL, Tai KS, Stacey B. Burden of illness in painful diabetic peripheral neuropathy: The patients' perspectives. J Pain. 2006;7:892–900
  21. Grant DM, Mauskopf JA, Bell L, Austin R. Comparison of valaciclovir and acyclovir for the treatment of herpes zoster in immunocompetent patients over 50 years of age: A cost-consequence model. Pharmacotherapy. 1997;17:333–341
  22. Hornburger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med. 2006;145:317–325
  23. Insinga RP, Itzler RF, Pellissier JM. Acute/subacute herpes zoster: Healthcare resource utilisation and costs in a group of US health plans. Pharmacoeconomics. 2007;25:155–169
  24. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: Review and implications. Neurology. 2007;68:1178–1182
  25. Lachaine J, Gordon A, Choinière M, Collet J, Dion D, Tarride J. Painful neuropathic disorders: An analysis of the Régie de l'Assurance Maladie du Québec database. Pain Res Manage. 2007;12:31–37
  26. McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: Results from a cross-sectional survey. Eur J Pain. 2006;10:127–135
  27. Meyer-Rosberg K, Kvarnstrom A, Kinnman E, Gordh T, Nordfors LO, Kristofferson A. Peripheral neuropathic pain: A multidimensional burden for patients. Eur J Pain. 2001;5:379–389
  28. Morbidity and Mortality Weekly Report. State-specific incidence of diabetes among adults: Participating states, 1995-1997 and 2005-2007. MMWR. 2008;57:1169–1173
  29. Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CPN, Sessle BJ, et al. Pharmacological management of chronic neuropathic pain: Consensus statement and guidelines from the Canadian Pain Society. Pain Res Manage. 2007;12:13–21
  30. O'Connor AB. Neuropathic pain: A review of the quality-of-life impact, costs, and cost effectiveness of therapy. Pharmacoeconomics. 2009;27:1–18
  31. O'Connor AB, Noyes K, Holloway RG. A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia. J Am Geriatr Soc. 2007;55:1176–1184
  32. O'Connor AB, Noyes K, Holloway RG. A cost-utility comparison of four first-line medications in painful diabetic neuropathy. Pharmacoeconomics. 2008;26:1045–1064
  33. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–2284
  34. Russell ML, Schopflocher DP, Svenson L, Virani SN. Secular trends in the epidemiology of shingles in Alberta. Epidemiol Infect. 2007;135:908–913
  35. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18:350–354
  36. Schmader K, Gnann JW, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis. 2008;197:S207–S2152008
  37. Schuette MC, Hethcote HW. Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles. Bull Math Biol. 1999;61:1031–1064
  38. Stein AN, Britt H, Harrison C, Conway EL, Cunningham A, MacIntyre CR. Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older. Vaccine. 2009;27:520–529
  39. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster?. Lancet Infect Dis. 2004;4:26–33
  40. Treede R-D, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630–1635
  41. Yih WK, Brooks DR, Lett SM, Jumaan AO, Zhang Z, Clements KM, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health. 2005;5:68

 Supported by grants from NeurogesX, Inc, to the University of Rochester Office of Continuing Professional Education, IMS Health Inc (formerly Health Benchmarks, Inc), Strategic Therapeutics, and Sissi Pham Consulting, Inc. Dr Dworkin has received research support, consulting fees, or honoraria in the past year from Allergan, Alpharma, Arcion, Astellas, AstraZeneca, BioLineRx, Boehringer Ingelheim, Cara, Cervelo, Durect, Eisai, Endo, Forest, Genzyme, Grünenthal, Johnson & Johnson, KAI Pharmaceuticals, Lilly, Merck, NeurogesX, Neuromed, Nuvo, Ono, Pfizer, Philips Respironics, Sanofi Aventis, Solace, UCB Pharma, US Department of Veterans Affairs, US National Institutes of Health, Wyeth, Xenon, and XTL Biopharmaceuticals and is a Special Government Employee of the US Food and Drug Administration Center for Drug Evaluation and Research; Drs Malone and Armstrong have received consulting fees in the past year from NeurogesX through Strategic Therapeutics; Dr Panarites owns shares of Covance, Johnson & Johnson, and Sanofi-Aventis and is an employee of NeurogesX; and Dr Pham owns shares of Glaxo SmithKline and in the past year has received consulting fees from Bristol-Myers Squibb, General Electric, NeurogesX, and Zelos.

PII: S1526-5900(09)00693-2

doi: 10.1016/j.jpain.2009.08.005

The Journal of Pain
Volume 11, Issue 4 , Pages 360-368 , April 2010

Article Tools

* Image Usage & Resolution